Benchmark Initiates Buy Rating for Prenetics Global Limited (PRE) Amid Strong IM8 Performance
Prenetics Global Limited (NASDAQ:PRE) received a 'Buy' rating from Benchmark with a $30 price target, driven by the strong performance of its IM8 health and wellness brand. The company reported Q1 revenue of $36 million, primarily from IM8, and raised its 2026 full-year revenue outlook for the segment to between $190 million and $210 million.
Tickers: $PRE
Topics: biotechnology consumer wellness health sciences supplements market